Clinical Research Studies
SPECIALIZING IN NOVEL AND INNOVATIVE RESEARCH APPROACHES FOR ALL TYPES OF CLINICAL DEPRESSION
***Due to current Covid-19 regulations, some studies are currently enrolling via televisits. We will be reviewing new applicants and enrolling when permitted. Please be aware that response times may be greater than usual during this time. ***
Currently Enrolling Studies
RELIANCE-II: A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder.
Eligible participants will either receive the study drug, REL-1017, or placebo. Esmethadone (also known as dextromethadone) is the active ingredient in REL-1017 tablets. This study drug selectively works on nerve cells that seem to play a role in depression. A placebo is an inactive tablet that looks identical to the study drug (tablet) but does not contain the active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.
The main goals of this study are to learn how safe the study drug is and how well the study drug works when taken with the antidepressants you are currently taking for MDD.
For further details, please see the following link: https://clinicaltrials.gov/ct2/show/NCT04855747